Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
J Neurooncol
; 89(2): 179-85, 2008 Sep.
Article
em En
| MEDLINE
| ID: mdl-18431544
ABSTRACT
BACKGROUND:
Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy.PURPOSE:
The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status.METHODS:
Progressive radio and chemotherapy naïve low grade glioma patients with O(6)-methyl-guanine-DNA-methyl-tranferase (MGMT) promoter status evaluation were considered eligible. Chemotherapy cycles consisted of temozolomide 75 mg/m(2)/daily for 21 days every 28 days for 12 cycles.RESULTS:
A total of 30 patients (median age 45 [range 24.2-68.6] years) with a median KPS of 90 (range 60-90) were accrued. The overall response rate was 30% (9 partial responses); 17 patients (56.7%) had disease stabilization.CONCLUSION:
The prolonged temozolomide schedule considered in the present study is followed by a high response rate; toxicity is acceptable. Further randomized trials should therefore be conducted to confirm the efficacy of this regimen as first-line therapy in patients with progressive low grade glioma.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Antineoplásicos Alquilantes
/
Dacarbazina
/
Glioma
/
Recidiva Local de Neoplasia
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article